Clinical Study Results
Research Sponsor: Acerta Pharma BV, a member of AstraZeneca group of companies
Treatment Studied: Acalabrutinib
Study Purpose: This study was done to learn how acalabrutinib works and about its safety in participants with leukemia
Protocol Number: 15-H-0016
Thank you for taking part in the clinical study for the study treatment acalabrutinib.
You and all of the participants helped researchers learn more about acalabrutinib to help people with leukemia.
Acerta Pharma BV, a member of AstraZeneca group of companies sponsored this study and believes it is important to share the results of the study with you and the public. An independent non-profit organization called CISCRP helped prepare this summary of the study results for you. We hope it helps you understand and feel proud of your important role in medical research.
If you participated in the study and have questions about the results, please speak with the study doctor or staff at your study site.